Three women sue cancer diagnostic firm Grail alleging harassment, retaliation

Three sales executives, all of them women, have filed suit against Grail, a cancer diagnostics company, alleging that they were harassed, that the company failed to take corrective action, and that it retaliated by removing them from consideration for promotions.

The suits, which were filed earlier this week, are complicated by the fact that Grail was purchased by Illumina, the largest DNA sequencing firm, for $8 billion in 2021 — yet Illumina has left Grail to operate as a separate company. Illumina is named in the suit.

All three plaintiffs are being represented by the Vora Law Firm, based in Santa Monica, Calif.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In